Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Sankyo Pharma Gmbh |
---|---|
Information provided by: | Daiichi Sankyo Inc. |
ClinicalTrials.gov Identifier: | NCT00185185 |
This is a study in hypertensive patients with atherosclerosis and increased cardiovascular risk. The efficacy of olmesartan medoxomil on atherosclerosis is measured.
Condition | Intervention | Phase |
---|---|---|
Essential Hypertension Atherosclerotic Cardiovascular Disease |
Drug: Olmesartan medoxomil Drug: Atenolol Drug: Hydrochlorothiazide Drug: olmesartan medoxomil Drug: atenolol |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Multi-Centre Olmesartan Atherosclerosis Regression Evaluation (MORE) |
Enrollment: | 165 |
Study Start Date: | November 2001 |
Study Completion Date: | February 2006 |
Arms | Assigned Interventions |
---|---|
1: Experimental
olmesartan medoxomil
|
Drug: Olmesartan medoxomil
Drug: Hydrochlorothiazide
tablets
Drug: olmesartan medoxomil
tablets
|
2: Active Comparator
atenolol
|
Drug: Atenolol
Drug: Hydrochlorothiazide
tablets
Drug: atenolol
tablets
|
Ages Eligible for Study: | 35 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Daichi Sankyo Europe, GmbH ( Petra Laeis ) |
Study ID Numbers: | SE-866/27 |
Study First Received: | September 12, 2005 |
Last Updated: | December 12, 2007 |
ClinicalTrials.gov Identifier: | NCT00185185 |
Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
Arterial Occlusive Diseases Atherosclerosis Vascular Diseases Olmesartan medoxomil Essential hypertension |
Arteriosclerosis Angiotensin II Atenolol Hydrochlorothiazide Hypertension |
Sympatholytics Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Adrenergic Agents Sodium Chloride Symporter Inhibitors Diuretics Physiological Effects of Drugs Cardiovascular Agents Antihypertensive Agents Pharmacologic Actions |
Angiotensin II Type 1 Receptor Blockers Membrane Transport Modulators Natriuretic Agents Autonomic Agents Therapeutic Uses Adrenergic beta-Antagonists Cardiovascular Diseases Adrenergic Antagonists Anti-Arrhythmia Agents Peripheral Nervous System Agents |